Behçet Disease

Ideguchi, Haruko; Suda, Arnold J.; Takeno, Mitsuhiro; Ueda, Atsushi; Ohno, Shigeru; Ishigatsubo, Yoshiaki

doi:10.1097/md.0b013e318211bf28

Cited by 136 publications

(49 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1] Involvement of the intestinal tract (intestinal BD), the nervous system (neurological BD [NBD]), and the vascular system (vascular BD [VBD]) is rare, although such cases tend to have a poor prognosis. [2,3] …”

Section: Introductionmentioning

confidence: 99%

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

Behçet disease (BD) is a multisystem disease associated with a poor prognosis in cases of gastrointestinal, neurological, or vascular involvement. We conducted a multicenter, prospective, open-label, single-arm phase 3 study to determine the efficacy, safety, and pharmacokinetics of infliximab (IFX) in BD patients with these serious complications who had displayed poor response or intolerance to conventional therapy.IFX at 5 mg/kg was administered to 18 patients (11 intestinal BD, 3 neurological BD [NBD], and 4 vascular BD [VBD]) at weeks 0, 2, and 6 and every 8 weeks thereafter until week 46. In patients who showed inadequate responses to IFX after week 30, the dose was increased to 10 mg/kg. We then calculated the percentage of complete responders according to the predefined criteria depending on the symptoms and results of examinations (ileocolonoscopy, brain magnetic resonance imaging, computed tomography angiography, positron emission tomography, cerebrospinal fluid, or serum inflammatory markers), exploring the percentage of complete responders at week 30 (primary endpoint).The percentage of complete responders was 61% (11/18) at both weeks 14 and 30 and remained the same until week 54. Intestinal BD patients showed improvement in clinical symptoms along with decrease in C-reactive protein (CRP) levels after week 2. Consistently, scarring or healing of the principal ulcers was found in more than 80% of these patients after week 14. NBD patients showed improvement in clinical symptoms, imaging findings, and cerebrospinal fluid examinations. VBD patients showed improvement in clinical symptoms after week 2 with reductions in CRP levels and erythrocyte sedimentation rate. Imaging findings showed reversal of inflammatory changes in 3 of the 4 VBD patients. Irrespective of the type of BD, all patients achieved improvement in quality of life, leading to the dose reduction or withdrawal of steroids. IFX dose was increased to 10 mg/kg in 3 intestinal BD patients, resulting in the improvement of clinical symptoms, CRP levels, and visual analogue scale score. Safety and pharmacokinetics profiles were comparable to those in patients with rheumatoid arthritis or Crohn disease. These findings support IFX as a new therapeutic option for patients with intestinal BD, NBD, or VBD.

show abstract

Section: Introductionmentioning

confidence: 99%

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similar to oral ulcers, genital ulcers are also more frequent in females [11, 21, 24–28]. In males, scrotum is more likely to be involved whereas in females, genital ulcers are frequently seen on labia majora and minora [29].…”

Section: Gender Differences In Extraocular Manifestations Of Behçementioning

confidence: 99%

“…Some reports revealed high frequencies in females (56%) [24, 35] whereas some reports indicated similar incidence in both sexes [26]. It is usually mono- or oligoarticular arthritis and typically resolves in a few weeks without deformity or radiological erosions.…”

Section: Gender Differences In Extraocular Manifestations Of Behçementioning

confidence: 99%

Gender Differences in Behçet’s Disease Associated Uveitis

Ucar-Comlekoglu

Fox

Sen

2014

Journal of Ophthalmology

View full text Add to dashboard Cite

Behçet's disease is a systemic vasculitis of unknown etiology, characterized by oral and genital ulceration, skin lesions, and uveitis as well as vascular, central nervous system, and gastrointestinal system involvement. It is prevalent in the Middle East, Mediterranean, and Eastern Asia. The aim of this review is to evaluate the gender differences in clinical manifestations of Behçet's disease, treatment responses, mortality, and morbidity. Behçet's disease has been reported to be more prevalent in males from certain geographic regions and particular ethnic groups; however, recent reports indicate more even gender distribution across the world. There are gender differences in clinical manifestations and severity of the disease. Ocular manifestations, vascular involvement, and neurologic symptoms are more frequently reported in male patients whereas oral and genital ulcers, skin lesions, and arthritis occur more frequently in female patients. The disease can have a more severe course in males, and overall mortality rate is significantly higher among young male patients.

show abstract

“…Almost all aspects of BD is a source of debate and even its diagnostic criteria, classification, and pathogenesis are controversial [2–4]. …”

Section: Introductionmentioning

confidence: 99%

Histopathological Evaluation of Behçet's Disease and Identification of New Skin Lesions

Gündüz

2012

Pathology Research International

View full text Add to dashboard Cite

Behçet's disease (BD) is a multisystemic, relapsing inflammatory disorder with an obscure etiology and pathogenesis. Diagnosis depends on the clinician's ability to identify a group of nonspecific mucocutaneous lesions, which also manifest in a number of other diseases. In recent years, there has been an increase in the studies focusing on the histopathological aspects of Behçet's disease diagnostic mucocutaneous lesions. Their results emphasize the value of histopathology and direct immunofluorescence (DIF) in the differential diagnosis of Behçet's disease.

show abstract

Behçet Disease

Cited by 136 publications

References 23 publications

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease

Gender Differences in Behçet’s Disease Associated Uveitis

Histopathological Evaluation of Behçet's Disease and Identification of New Skin Lesions

Contact Info

Product

Resources

About